Literature DB >> 8106113

Enhanced recovery of the nigrostriatal dopaminergic system in MPTP-treated mice following intrastriatal injection of basic fibroblast growth factor in relation to aging.

I Date1, Y Yoshimoto, T Imaoka, Y Miyoshi, Y Gohda, T Furuta, S Asari, T Ohmoto.   

Abstract

Studies have suggested that the restorative effects of adrenal medullary chromaffin cell grafts in animal models of Parkinson's disease may be related to trophic factors contained within the chromaffin cells. Basic fibroblast growth factor (bFGF) is present in chromaffin cells and has been shown to exert trophic effects on dopaminergic neurons in vitro. Basic FGF was stereotaxically injected into the striatum of young (2-month-old) and aging (12-month-old) C57BL/6 mice which had been treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 1 week earlier. MPTP treatment reduced tyrosine hydroxylase (TH)-immunoreactive (IR) fibers in the striatum and striatal dopamine (DA) concentration in both the young and older mice 5 weeks later. Computerized image analysis of striatal DA fibers in young mice treated with bFGF showed significant recovery of DA fibers up to 600 microns from the injection site 5 weeks after MPTP administration. Striatal DA fibers in older mice treated with bFGF showed significant recovery only up to 300 microns from the injection site, and the degree of recovery was very limited compared with young mice. HPLC analysis of DA concentration revealed that striatal DA in young mice recovered significantly when treated with bFGF, but no significant recovery was observed in older mice. It is concluded that bFGF enhances the recovery of striatal DA systems from MPTP toxicity both in young and in older mice, but that such benefits are very limited in older mice.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8106113     DOI: 10.1016/0006-8993(93)90312-b

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  18 in total

Review 1.  Neural transplantation for Parkinson's disease.

Authors:  I Date; T Ohmoto
Journal:  Cell Mol Neurobiol       Date:  1999-02       Impact factor: 5.046

2.  CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice.

Authors:  Mikko Airavaara; Brandon K Harvey; Merja H Voutilainen; Hui Shen; Jenny Chou; Päivi Lindholm; Maria Lindahl; Raimo K Tuominen; Mart Saarma; Barry Hoffer; Yun Wang
Journal:  Cell Transplant       Date:  2011-09-22       Impact factor: 4.064

3.  Fibroblast growth factor 2 enhances striatal and nigral neurogenesis in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

Authors:  J Peng; L Xie; K Jin; D A Greenberg; J K Andersen
Journal:  Neuroscience       Date:  2008-03-07       Impact factor: 3.590

Review 4.  Early detection of Parkinson's disease. Implications for treatment.

Authors:  R Di Paola; R J Uitti
Journal:  Drugs Aging       Date:  1996-09       Impact factor: 3.923

Review 5.  Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations.

Authors:  R G Thorne; W H Frey
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

6.  Glutamate controls growth rate and branching of dopaminergic axons.

Authors:  Yvonne Schmitz; James Luccarelli; Minji Kim; Mi Wang; David Sulzer
Journal:  J Neurosci       Date:  2009-09-23       Impact factor: 6.167

Review 7.  Neurotrophic factors in neurodegenerative disorders : potential for therapy.

Authors:  Fabio Fumagalli; Raffaella Molteni; Francesca Calabrese; Paola Francesca Maj; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

8.  PEGylated rhFGF-2 conveys long-term neuroprotection and improves neuronal function in a rat model of Parkinson's disease.

Authors:  Guanghui Zhu; Ganping Chen; Lu Shi; Jenny Feng; Yan Wang; Chaohui Ye; Wenke Feng; Jianlou Niu; Zhifeng Huang
Journal:  Mol Neurobiol       Date:  2014-06-15       Impact factor: 5.590

9.  Myelin basic protein-primed T cells induce neurotrophins in glial cells via alphavbeta3 [corrected] integrin.

Authors:  Avik Roy; Xiaojuan Liu; Kalipada Pahan
Journal:  J Biol Chem       Date:  2007-09-06       Impact factor: 5.157

10.  Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease.

Authors:  Anamitra Ghosh; Avik Roy; Joanna Matras; Saurav Brahmachari; Howard E Gendelman; Kalipada Pahan
Journal:  J Neurosci       Date:  2009-10-28       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.